Drugs / Radspherin
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03732768 | Jun 2020 → Sep 2025 | ovarian cancer, peritoneal carcinomatosis | Oncoinvent Solutions AS | Completed | No outcome recorded |
| Phase 1/21 trial · 1 met primary | ||||||
| Phase 1/2 | NCT03732781 | May 2020 → May 2025 | colorectal carcinoma, peritoneal carcinoma | Oncoinvent Solutions AS | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT06504147 | Jun 2024 → Feb 2028 expected | ovarian cancer, peritoneal carcinomatosis | Oncoinvent Solutions AS | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 24
| Date | Issuer | Release |
|---|---|---|
| 2026-08-11 | Oncoinvent Solutions AS | Results Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine oncoinvent.com ↗
The publication, titled “ Normal Tissue Dosimetry of Intraperitoneal Radium-224-Microparticle Therapy: Data from First-in-Human Studies in Patients with Peritoneal Metastases ” , r eports results from nine patients enrolled in the dosimetry cohorts of the Phase 1 Radspherin ® studies in ovarian and colorectal cancer. |
| 2026-03-19 | Oncoinvent Solutions AS | Regulatory Oncoinvent secures new patent expanding protection for Radspherin[®] oncoinvent.com ↗
today announces that the China National Intellectual Property Administration (CNIPA) has granted a new patent for Radspherin ® |
| 2026-02-17 | Oncoinvent Solutions AS | Results Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026 oncoinvent.com ↗
Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose experienced peritoneal recurrence |
| 2025-12-08 | Oncoinvent Solutions AS | Results Oncoinvent Announces Publication of Phase 1 Study Results for Radspherin® in Ovarian Cancer in Gynecologic Oncology oncoinvent.com ↗
Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. |
| 2025-10-29 | Oncoinvent Solutions AS | Results Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies oncoinvent.com ↗
Oncoinvent Presents Final Safety and Efficacy Results from the Phase 1/2a Trial of Radspherin® to Treat Colorectal Cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies |
| 2025-10-08 | Oncoinvent Solutions AS | Results Oncoinvent Reports Positive Final Data from Phase 1 Trial of Radspherin® to Treat Ovarian Cancer oncoinvent.com ↗
The final 24-month data still reports that only 1 of these 10 patients had peritoneal recurrence, and peritoneal recurrence rate remains at 10%. |
| 2025-06-18 | Oncoinvent Solutions AS | Results Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases oncoinvent.com ↗
Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, is thrilled to announce positive topline data from the Phase 1/2a clinical trial (RAD-18-002) evaluating Radspherin® in patients with peritoneal metastases originating from colorectal cancer. |
| 2025-04-28 | Oncoinvent Solutions AS | Results Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression oncoinvent.com ↗
At the 18-month follow-up, no further patient had experienced recurrence. |
| 2025-03-25 | Oncoinvent Solutions AS | Results Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients oncoinvent.com ↗ |
| 2024-11-11 | Oncoinvent Solutions AS | Results Oncoinvent Announces Promising Interim Results for Radspherin® as a Potential Treatment for Peritoneal Carcinomatosis oncoinvent.com ↗
We are excited to announce the interim results of our Phase1/2a studies of Radspherin®, confirming a positive efficacy signal and demonstrating Radspherin’s® ability to enable local control in the peritoneum, thus ensuring patients remain in remission after surgery |
| 2024-11-01 | Oncoinvent Solutions AS | Results Oncoinvent Announces Publication of 18-Month Safety and Efficacy Data from the Phase 1/2a Study of Radspherin® in Colorectal Cancer oncoinvent.com ↗
At 18 months, none of the patients receiving the recommended dose (7 MBq) had peritoneal recurrences. |
| 2024-06-24 | Oncoinvent Solutions AS | Regulatory Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer oncoinvent.com ↗
Oncoinvent Receives FDA Fast Track Designation for Radspherin® as Treatment for Peritoneal Carcinomatosis from Ovarian Cancer |
| 2023-10-31 | Oncoinvent Solutions AS | Regulatory Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Ovarian Cancer Patients oncoinvent.com ↗
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2 study for Radspherin® in patients with peritoneal carcinomatosis from ovarian cancer. |
| 2023-10-27 | Oncoinvent Solutions AS | Regulatory Oncoinvent Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for Radspherin® in Colorectal Cancer Patients oncoinvent.com ↗
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for the phase 2b study for Radspherin® in patients with peritoneal carcinomatosis from colorectal cancer. |
| 2023-10-04 | Oncoinvent Solutions AS | Results Oncoinvent Presents Preliminary 18-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 13th PSOGI International Congress on Peritoneal Surface Malignancies oncoinvent.com ↗
At 18 months, none of the patients administered Radspherin® at the recommended dose experienced peritoneal recurrences. |
| 2023-06-05 | Oncoinvent Solutions AS | Results Oncoinvent Presents 15-Month Safety and Efficacy Data from Ongoing RAD-18-002 Phase 1/2A Trial of Radspherin® in Colorectal Cancer Patients at the 2023 ASCO Annual Meeting oncoinvent.com ↗ |
| 2023-04-21 | Oncoinvent Solutions AS | Results Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes oncoinvent.com ↗
The second, titled “First experience with 224 Radium-labeled microparticles (Radspherin®) after CRS-HIPEC for peritoneal metastasis in colorectal cancer (a phase 1 study),” supports the favorable safety profile of Radspherin® and establishes sustained tolerability in all dose levels for patients treated to date with colorectal cancer. |
| 2023-02-10 | Oncoinvent Solutions AS | Results Oncoinvent updates: Phase I dose escalation completed successfully in two indications Phase 2 A inclusion has started oncoinvent.com ↗
The 12 Patients that received the recommended clinical dose of 7 MBq in the RAD-18-002 study remain disease free in the peritoneal cavity at the 12-months read out time point. |
| 2021-10-21 | Oncoinvent Solutions AS | Results Oncoinvent to present four posters at the 34th Annual Congress of the European Association of Nuclear Medicine oncoinvent.com ↗
These data demonstrate that Radspherin® has potentially robust and retained biodistribution in body cavities, and give us important insights into the safety of clinical doses. |
| 2021-04-09 | Oncoinvent Solutions AS | Results Safety Monitoring Committee Approves 7 MBq as Recommended Clinical Dose for Radspherin® in the Ongoing RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients oncoinvent.com ↗
the Safety Monitoring Committee for the RAD-18-002 clinical trial has concluded that the 7 MBq dose of Radspherin ® to be safe |
| 2019-02-19 | Oncoinvent Solutions AS | Regulatory Oncoinvent receives manufacturing authorization for clinical trial material oncoinvent.com ↗
Oncoinvent receives manufacturing authorization for clinical trial material |
| 2018-04-05 | Oncoinvent Solutions AS | Results Oncoinvent publishes data explaining Radspherin® `s mechanism of action oncoinvent.com ↗
Data describing and explaining Radspherin® `s mechanism of action has been published in the Journal of Labelled Compounds and Radiopharmaceuticals. |
| 2018-01-31 | Oncoinvent Solutions AS | Results New Radspherin® data published oncoinvent.com ↗
In both models, intraperitoneal treatment with Radspherin® gave significant antitumor effect with either considerably reduced tumor volume or a survival benefit. |
| 2017-10-23 | Oncoinvent Solutions AS | Results Oncoinvent presents Radspherin® preclinical data at 30th Annual Congress of the European Association of Nuclear Medicine (EANM) oncoinvent.com ↗
Oncoinvent, a preclinical stage company committed to developing new innovative products to provide better treatment options to cancer patients, announced new data from the ongoing preclinical development of Radspherin®. |
All press releases naming this drug 43 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radspherin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03732781 ↗ |
| Modality | Other / unclassified | “the alpha emitting therapy 224Ra-labeled microparticles (Radspherin®)” PMID 41349345 ↗ Dec 2025 |
| Route | Other | “Radspherin® was administered intraperitoneally 2 days after CRS-HIPEC” PMID 36936230 ↗ Mar 2023 |